Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
Key words
CML, chronic myeloid leukemia, mutation, protein kinase inhibitor, antineoplastic, ponatinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined